Surmodics (SRDX) Receiving Somewhat Favorable News Coverage, Study Finds

Media headlines about Surmodics (NASDAQ:SRDX) have trended somewhat positive this week, Accern reports. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Surmodics earned a news impact score of 0.20 on Accern’s scale. Accern also assigned news articles about the company an impact score of 44.3547061734327 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:

Several brokerages have recently issued reports on SRDX. ValuEngine upgraded Surmodics from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. BidaskClub upgraded Surmodics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Lake Street Capital began coverage on Surmodics in a research report on Friday, July 14th. They set a “buy” rating and a $40.00 price objective for the company. Finally, Aegis began coverage on Surmodics in a research report on Tuesday, June 27th. They set a “buy” rating for the company. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the stock. Surmodics has an average rating of “Hold” and an average target price of $34.33.

Surmodics (SRDX) traded up 7.17% during midday trading on Monday, reaching $29.90. The company’s stock had a trading volume of 47,460 shares. The stock has a market capitalization of $391.96 million, a price-to-earnings ratio of 65.14 and a beta of 0.85. The firm has a 50-day moving average price of $26.04 and a 200 day moving average price of $25.06. Surmodics has a 52-week low of $21.90 and a 52-week high of $30.75.

Surmodics (NASDAQ:SRDX) last issued its earnings results on Thursday, August 3rd. The company reported $0.09 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.10. The business had revenue of $17.80 million for the quarter, compared to analyst estimates of $15.98 million. Surmodics had a net margin of 8.66% and a return on equity of 7.28%. Surmodics’s revenue was down 11.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.37 earnings per share. Equities research analysts predict that Surmodics will post $0.31 EPS for the current fiscal year.

In other Surmodics news, CEO Gary R. Maharaj sold 5,000 shares of the company’s stock in a transaction on Monday, August 7th. The shares were sold at an average price of $25.75, for a total transaction of $128,750.00. Following the transaction, the chief executive officer now owns 126,807 shares in the company, valued at $3,265,280.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, VP Joseph J. Stich sold 1,000 shares of the company’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $27.28, for a total transaction of $27,280.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 11,000 shares of company stock worth $296,180. Corporate insiders own 6.40% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Surmodics (SRDX) Receiving Somewhat Favorable News Coverage, Study Finds” was reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at

Surmodics Company Profile

Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.

Insider Buying and Selling by Quarter for Surmodics (NASDAQ:SRDX)

Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply